Protein / target
Isocitrate dehydrogenase [NADP] cytoplasmic
Protein at a glance
Biological role
Isocitrate dehydrogenase (NADP+) activity
Primary system
Endocrine & metabolic
Strongest disease association
Ollier disease
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
3 approved · 4 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase (PubMed:10521434, PubMed:19935646). Plays a critical role in the generation of NADPH, an important cofactor in many biosynthesis pathways (PubMed:10521434). May act as a corneal epithelial crystallin and may be involved in maintaining corneal epithelial transparency (By similarity)
Subcellular location
Domains and Gene Ontology detail (25)Hide
Gene Ontology
- Ccytoplasm
- Ccytosol
- Cextracellular exosome
- Cextracellular region
- Cficolin-1-rich granule lumen
- Cmitochondrion
- Cperoxisomal matrix
- Cperoxisome
- Csecretory granule lumen
- Ctertiary granule lumen
- Fcadherin binding
- Fidentical protein binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Metabolic enzyme activity
- ·isocitrate dehydrogenase (NADP+) activity
- ·2-oxoglutarate metabolic process
- ·isocitrate metabolic process
- ·NADP+ metabolic process
View underlying pathways (5)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
Appears in clinical studies involving acute myeloid leukemia, acute myeloid leukemia by FAB classification, cholangiocarcinoma, myelodysplastic syndrome
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 827 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 8 total
glioma
acute myeloid leukemia by FAB classification · acute myeloid leukemia
acute myeloid leukemia by FAB classification · acute myeloid leukemia · myelodysplastic syndrome
astrocytoma (excluding glioblastoma) · oligodendroglioma · paraganglioma
acute myeloid leukemia · acute myeloid leukemia by FAB classification · cholangiocarcinoma
astrocytoma (excluding glioblastoma) · oligodendroglioma · glioma
paraganglioma · low grade glioma · acute myeloid leukemia
neoplasm
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Trial status changed
An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
- Regulatory approval
Approval: Tibsovo (EMA)
- New publicationFinal Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.